Ísrael - hebreska - Ministry of Health

taro international ltd - clopidogrel 75 mg - film coated tablets - clopidogrel - clopidogrel is indicated in adults for the prevention of atherothrombotic events as follows:patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.patients suffering from acute coronary syndrome- non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave myocardial infarction (mi)), including patients undergoing a stent replacement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy

Ísrael - hebreska - Ministry of Health

rafa laboratories ltd - dipyridamole - טבליה - dipyridamole 75 mg - dipyridamole - dipyridamole - as an adjunct to oral anticoagulants for prophylaxis of thromboembolism associated with prosthetic heart valves. reduction of proteinuria in the nephrotis syndrome. treatment of membranoproliferative glomerulonephritis. prevention of pre-eclampsia in the final trimester of pregnancy. prevention of transplant artery stenosis. prevention of post-operative thromboembolic complications of coronary artery surgery. in combination with acetylsalicylic acid in cases of recurrent deep vein thrombosis resistant to oral anticoagulants. prevention of thrombogenic manifestations. as an alternative to exercise stress in thallium myocardial imaging particularly in patients unable to exercise or in those for whom exercise may be contraindicated.

Ísrael - hebreska - Ministry of Health

astrazeneca (israel) ltd - ticagrelor - טבליות מצופות פילם - ticagrelor 90 mg - ticagrelor - ticagrelor - brilinta, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with acute coronary syndromes (unstable angina, non st elevation myocardial infarction [nstemi] or st elevation myocardial infarction [stemi]); including patients managed medically, and those who are managed with percutaneous coronary intervention (pci) or coronary artery by-pass grafting (cabg).

Ísrael - hebreska - Ministry of Health

padagis israel pharmaceuticals ltd, israel - fluvoxamine maleate - טבליה - fluvoxamine maleate 100 mg - fluvoxamine - fluvoxamine - for the treatment of affective disorders characterized by persistent low mood, impaired psychomotor atctivities and psychomatic complaints including symptoms of depression. treatment of obsessive compulsive disorders (ocd).

Ísrael - hebreska - Ministry of Health

padagis israel pharmaceuticals ltd, israel - fluvoxamine maleate - טבליה - fluvoxamine maleate 50 mg - fluvoxamine - fluvoxamine - for the treatment of affective disorders characterized by persistent low mood, impaired psychomotor atctivities and psychomatic complaints including symptoms of depression. treatment of obsessive compulsive disorders (ocd).

Ísrael - hebreska - Ministry of Health

eli lilly israel ltd - prasugrel as hydrochloride - טבליות מצופות פילם - prasugrel as hydrochloride 5 mg - platelet aggregation inhibitors, excl. heparin - effient, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in patients with acute coronary syndrome ( i.e. unstable angina, non-st segment elevation myocardial infarction [ua/nstemi] or st segment elevation myocardial infarction [stemi] undergoing primary or delayed percutaneous coronary intervention (pci).the increased efficacy should be balanced with the increased risk in patients with bleeding tendencyin those who had tia/cva in the past and in those above the age of 75 and a weight below 60 kg3.

Ísrael - hebreska - Ministry of Health

eli lilly israel ltd - prasugrel as hydrochloride - טבליות מצופות פילם - prasugrel as hydrochloride 10 mg - platelet aggregation inhibitors, excl. heparin - effient, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in patients with acute coronary syndrome ( i.e. unstable angina, non-st segment elevation myocardial infarction [ua/nstemi] or st segment elevation myocardial infarction [stemi] undergoing primary or delayed percutaneous coronary intervention (pci). the increased efficacy should be balanced with the increased risk in patients with bleeding tendencyin those who had tia/cva in the past and in those above the age of 75 and a weight below 60 kg3.

Ísrael - hebreska - Ministry of Health

taro pharmaceutical industries ltd - rivaroxaban - טבליות מצופות פילם - rivaroxaban 15 mg - rivaroxaban

Ísrael - hebreska - Ministry of Health

taro pharmaceutical industries ltd - rivaroxaban - טבליות מצופות פילם - rivaroxaban 20 mg - rivaroxaban

Ísrael - hebreska - Ministry of Health

teva israel ltd - rivaroxaban - טבליות מצופות פילם - rivaroxaban 15 mg - rivaroxaban